Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/14551
Epidemiological trends of HIV/HCV coinfection in Spain, 2015-2019
Fanciulli, Chiara | Berenguer, Juan | Busca, Carmen | Vivancos, María J | Téllez, María J | Domínguez, Lourdes | Domingo, Pere | Navarro, Jordi | Santos, Jesús | Iribarren, José A | Morano, Luis | Artero, Arturo | Moreno, Javier ISCIII | Rivero-Román, Antonio | Santos, Ignacio | Giner, Livia | Armiñanzas, Carlos | Montero, Marta | Manzardo, Christian | Cifuentes, Carmen | García, Coral | Galindo, María J | Ferrero, Oscar L | Sanz, José | de la Fuente, Belén | Rodríguez, Carmen | Gaspar, Gabriel | Pérez, Laura | Losa, Juan E | Force, Luis | Veloso, Sergio | Martínez-Alfaro, Elisa | Jarrin-Vera, Inmaculada ISCIII | De Miguel, Marta | González Garcia, Juan | GeSIDA 8514 Study Group
HIV Med. 2022 Aug;23(7):705-716.
Objectives: We assessed the prevalence of anti-hepatitis C virus (HCV) antibodies and active HCV infection (HCV-RNA-positive) in people living with HIV (PLWH) in Spain in 2019 and compared the results with those of four similar studies performed during 2015-2018. Methods: The study was performed in 41 centres. Sample size was estimated for an accuracy of 1%. Patients were selected by random sampling with proportional allocation. Results: The reference population comprised 41 973 PLWH, and the sample size was 1325. HCV serostatus was known in 1316 PLWH (99.3%), of whom 376 (28.6%) were HCV antibody (Ab)-positive (78.7% were prior injection drug users); 29 were HCV-RNA-positive (2.2%). Of the 29 HCV-RNA-positive PLWH, infection was chronic in 24, it was acute/recent in one, and it was of unknown duration in four. Cirrhosis was present in 71 (5.4%) PLWH overall, three (10.3%) HCV-RNA-positive patients and 68 (23.4%) of those who cleared HCV after anti-HCV therapy (p = 0.04). The prevalence of anti-HCV antibodies decreased steadily from 37.7% in 2015 to 28.6% in 2019 (p < 0.001); the prevalence of active HCV infection decreased from 22.1% in 2015 to 2.2% in 2019 (p < 0.001). Uptake of anti-HCV treatment increased from 53.9% in 2015 to 95.0% in 2019 (p < 0.001). Conclusions: In Spain, the prevalence of active HCV infection among PLWH at the end of 2019 was 2.2%, i.e. 90.0% lower than in 2015. Increased exposure to DAAs was probably the main reason for this sharp reduction. Despite the high coverage of treatment with direct-acting antiviral agents, HCV-related cirrhosis remains significant in this population.
- Investigación > IIS > IMIBIC - Instituto Maimónides de Investigación Biomédica de Córdoba (Andalucía) > IIS - Artículos
- Investigación > IIS > IiSGM - Instituto de Investigación Sanitaria Gregorio Marañón (Madrid) > IIS - Artículos
- Investigación > IIS > IRYCIS - Instituto Ramón y Cajal de Investigación Sanitaria (Madrid) > IIS - Artículos
- Investigación > IIS > IDIPAZ - Instituto de Investigación Sanitaria Hospital La Paz (Madrid) > IIS - Artículos
- Investigación > ISCIII > Centro Nacional de Epidemiología (CNE) > ISCIII - Artículos
Files in this item
- EpidemiologicalTrendsHIVHCV_20 ...